Obama Administration to Challenge Judge's Ruling on 'Morning-After' Pill
By Steven Reinberg
HealthDay Reporter
WEDNESDAY, May 1 (HealthDay News) -- A federal judge's order to eliminate any age limit on who can buy morning-after birth control pills without a prescription was challenged in court Wednesday by the Obama administration.
The government appeal follows on the heels of a Tuesday decision by the U.S. Food and Drug Administration to lower the age that people can buy the Plan B One-Step morning-after pill without a prescription to 15 - younger than the current limit of 17.
With the appeal, the government has signaled that it will only ease access to emergency contraception a certain amount, the Associated Press reported Wednesday night.
The emergency contraceptive is made by Teva Women's Health Inc.
"Research has shown that access to emergency contraceptive products has the potential to further decrease the rate of unintended pregnancies in the United States," FDA Commissioner Dr. Margaret Hamburg said in an agency news release.
"The data reviewed by the agency demonstrated that women 15 years of age and older were able to understand how Plan B One-Step works, how to use it properly and that it does not prevent the transmission of a sexually transmitted disease," she said.
To prevent girls under the age of 15 from buying Plan B, the FDA said the product will bear a label stating that proof of age will be required, and a special product code will prompt such an inquiry from the cashier. "In addition, Teva has arranged to have a security tag placed on all product cartons to prevent theft," the FDA noted.
On April 5, Judge Edward Korman, from the Eastern District of New York, gave the FDA 30 days to remove age restrictions on the sale of emergency contraception, such as Plan B One-Step. Until now, girls 16 and younger needed a doctor's prescription to get the pill, which typically works if taken within 72 hours after intercourse.
Other brands of emergency contraception include Next Choice and Ella.
The move is the latest chapter in a 10-year, controversial debate about who should have access to the drug and why.
HealthDay Reporter
WEDNESDAY, May 1 (HealthDay News) -- A federal judge's order to eliminate any age limit on who can buy morning-after birth control pills without a prescription was challenged in court Wednesday by the Obama administration.
The government appeal follows on the heels of a Tuesday decision by the U.S. Food and Drug Administration to lower the age that people can buy the Plan B One-Step morning-after pill without a prescription to 15 - younger than the current limit of 17.
With the appeal, the government has signaled that it will only ease access to emergency contraception a certain amount, the Associated Press reported Wednesday night.
The emergency contraceptive is made by Teva Women's Health Inc.
"Research has shown that access to emergency contraceptive products has the potential to further decrease the rate of unintended pregnancies in the United States," FDA Commissioner Dr. Margaret Hamburg said in an agency news release.
"The data reviewed by the agency demonstrated that women 15 years of age and older were able to understand how Plan B One-Step works, how to use it properly and that it does not prevent the transmission of a sexually transmitted disease," she said.
To prevent girls under the age of 15 from buying Plan B, the FDA said the product will bear a label stating that proof of age will be required, and a special product code will prompt such an inquiry from the cashier. "In addition, Teva has arranged to have a security tag placed on all product cartons to prevent theft," the FDA noted.
On April 5, Judge Edward Korman, from the Eastern District of New York, gave the FDA 30 days to remove age restrictions on the sale of emergency contraception, such as Plan B One-Step. Until now, girls 16 and younger needed a doctor's prescription to get the pill, which typically works if taken within 72 hours after intercourse.
Other brands of emergency contraception include Next Choice and Ella.
The move is the latest chapter in a 10-year, controversial debate about who should have access to the drug and why.
SHARE
